Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Metastasis | Research

The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma

Authors: Mengchao Xue, Junjie Liu, Zhenyi Li, Ming Lu, Huiying Zhang, Wen Liu, Hui Tian

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Identifying lymph node metastasis areas during surgery for early invasive lung adenocarcinoma remains challenging. The aim of this study was to develop a nomogram mathematical model before the end of surgery for predicting lymph node metastasis in patients with early invasive lung adenocarcinoma.

Methods

In this study, we included patients with invasive lung adenocarcinoma measuring ≤ 2 cm who underwent pulmonary resection with definite pathology at Qilu Hospital of Shandong University from January 2020 to January 2022. Preoperative biomarker results, clinical features, and computed tomography characteristics were collected. The enrolled patients were randomized into a training cohort and a validation cohort in a 7:3 ratio. The training cohort was used to construct the predictive model, while the validation cohort was used to test the model independently. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors. The prediction model and nomogram were established based on the independent risk factors. Recipient operating characteristic (ROC) curves were used to assess the discrimination ability of the model. Calibration capability was assessed using the Hosmer–Lemeshow test and calibration curves. The clinical utility of the nomogram was assessed using decision curve analysis (DCA).

Results

The overall incidence of lymph node metastasis was 13.23% (61/461). Six indicators were finally determined to be independently associated with lymph node metastasis. These six indicators were: age (P < 0.001), serum amyloid (SA) (P = 0.008); carcinoma antigen 125 (CA125) (P = 0. 042); mucus composition (P = 0.003); novel aspartic proteinase of the pepsin family A (Napsin A) (P = 0.007); and cytokeratin 5/6 (CK5/6) (P = 0.042). The area under the ROC curve (AUC) was 0.843 (95% CI: 0.779–0.908) in the training cohort and 0.838 (95% CI: 0.748–0.927) in the validation cohort. the P-value of the Hosmer–Lemeshow test was 0.0613 in the training cohort and 0.8628 in the validation cohort. the bias of the training cohort corrected C-index was 0.8444 and the bias-corrected C-index for the validation cohort was 0.8375. demonstrating that the prediction model has good discriminative power and good calibration.

Conclusions

The column line graphs created showed excellent discrimination and calibration to predict lymph node status in patients with ≤ 2 cm invasive lung adenocarcinoma. In addition, the predictive model has predictive potential before the end of surgery and can inform clinical decision making.

Available only for authorised users

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.PubMedCrossRef

Walter JE, Heuvelmans MA, de Jong PA, Vliegenthart R, van Ooijen PMA, Peters RB, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. Lancet Oncol. 2016;17(7):907–16.PubMedCrossRef

Kuroda H, Sakata S, Takahashi Y, Nakada T, Oya Y, Sugita Y, et al. Subsegmental resection preserves regional pulmonary function: a focus on thoracoscopy. Thorac Cancer. 2021;12(7):1033–40.PubMedPubMedCentralCrossRef

Iwata H, Shirahashi K, Mizuno Y, Yamamoto H, Takemura H. Feasibility of segmental resection in non-small-cell lung cancer with ground-glass opacity. Eur J Cardiothorac Surg. 2014;46(3):375–9 (discussion 9).PubMedCrossRef

Pani E, Kennedy G, Zheng X, Ukert B, Jarrar D, Gaughan C, et al. Factors associated with nodal metastasis in 2-centimeter or less non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020;159(3):1088-96.e1.PubMedCrossRef

Yu X, Li Y, Shi C, Han B. Risk factors of lymph node metastasis in patients with non-small cell lung cancer ≤ 2 cm in size: a monocentric population-based analysis. Thorac Cancer. 2018;9(1):3–9.PubMedCrossRef

Higgins KA, Chino JP, Ready N, D’Amico TA, Berry MF, Sporn T, et al. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. J Thorac Oncol. 2012;7(7):1141–7.PubMedCrossRef

Gdeedo A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Van Marck E. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J. 1997;10(7):1547–51.PubMedCrossRef

Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest. 2000;117(3):773–8.PubMedCrossRef

10.

Prenzel KL, Mönig SP, Sinning JM, Baldus SE, Brochhagen HG, Schneider PM, et al. Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest. 2003;123(2):463–7.PubMedCrossRef

11.

Sioris T, Järvenpää R, Kuukasjärvi P, Helin H, Saarelainen S, Tarkka M. Comparison of computed tomography and systematic lymph node dissection in determining TNM and stage in non-small cell lung cancer. Eur J Cardiothorac Surg. 2003;23(3):403–8.PubMedCrossRef

12.

Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 1997;202(2):441–6.PubMedCrossRef

13.

Hermens FH, Van Engelenburg TC, Visser FJ, Thunnissen FB, Termeer R, Janssen JP. Diagnostic yield of transbronchial histology needle aspiration in patients with mediastinal lymph node enlargement. Respiration. 2003;70(6):631–5.PubMedCrossRef

14.

Annema JT, Veseliç M, Versteegh MI, Willems LN, Rabe KF. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer. 2003;42(3):311–8.PubMedCrossRef

15.

FreixinetGilart J, García PG, de Castro FR, Suárez PR, Rodríguez NS, de Ugarte AV. Extended cervical mediastinoscopy in the staging of bronchogenic carcinoma. Ann Thorac Surg. 2000;70(5):1641–3.CrossRef

16.

Boffa DJ, Kosinski AS, Paul S, Mitchell JD, Onaitis M. Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. Ann Thorac Surg. 2012;94(2):347–53 (discussion 53).PubMedCrossRef

17.

Ohtaki Y, Yoshida J, Ishii G, Aokage K, Hishida T, Nishimura M, et al. Prognostic significance of a solid component in pulmonary adenocarcinoma. Ann Thorac Surg. 2011;91(4):1051–7.PubMedCrossRef

18.

Nitadori J, Bograd AJ, Kadota K, Sima CS, Rizk NP, Morales EA, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst. 2013;105(16):1212–20.PubMedPubMedCentralCrossRef

19.

Wu J, Chen J, Lv X, Yang Q, Yao S, Zhang D, et al. Clinical value of serum and exhaled breath condensate inflammatory factor IL-11 levels in non-small cell lung cancer: Clinical value of IL-11 in non-small cell lung cancer. Int J Biol Markers. 2021;36(2):64–76.PubMedCrossRef

20.

Chen JL, Wu JN, Lv XD, Yang QC, Chen JR, Zhang DM. The value of red blood cell distribution width, neutrophil-to-lymphocyte ratio, and hemoglobin-to-red blood cell distribution width ratio in the progression of non-small cell lung cancer. PLoS ONE. 2020;15(8):e0237947.PubMedPubMedCentralCrossRef

21.

Jiang C, Zhao M, Hou S, Hu X, Huang J, Wang H, et al. The indicative value of serum tumor markers for metastasis and stage of non-small cell lung cancer. Cancers (Basel). 2022;14(20):5064.PubMedCrossRef

22.

Moon Y, Choi SY, Park JK, Lee KY. Risk factors for occult lymph node metastasis in peripheral non-small cell lung cancer with invasive component size 3 cm or less. World J Surg. 2020;44(5):1658–65.PubMedCrossRef

23.

Liu S, Wang R, Zhang Y, Li Y, Cheng C, Pan Y, et al. Precise diagnosis of intraoperative frozen section is an effective method to guide resection strategy for peripheral small-sized lung adenocarcinoma. J Clin Oncol. 2016;34(4):307–13.PubMedCrossRef

24.

Su H, Xie H, Dai C, Zhao S, Xie D, She Y, et al. Procedure-specific prognostic impact of micropapillary subtype may guide resection strategy in small-sized lung adenocarcinomas: a multicenter study. Ther Adv Med Oncol. 2020;12:1758835920937893.PubMedPubMedCentralCrossRef

25.

Yeh YC, Nitadori J, Kadota K, Yoshizawa A, Rekhtman N, Moreira AL, et al. Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤ 3 cm: accuracy and interobserver agreement. Histopathology. 2015;66(7):922–38.PubMedPubMedCentralCrossRef

26.

Koike T, Koike T, Yamato Y, Yoshiya K, Toyabe S. Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients. J Thorac Oncol. 2012;7(8):1246–51.PubMedCrossRef

27.

Ye B, Cheng M, Li W, Ge XX, Geng JF, Feng J, et al. Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg. 2014;98(1):217–23.PubMedCrossRef

28.

Kanzaki R, Higashiyama M, Fujiwara A, Tokunaga T, Maeda J, Okami J, et al. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0–1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study. Lung Cancer. 2011;71(3):333–7.PubMedCrossRef

29.

Farjah F, Lou F, Sima C, Rusch VW, Rizk NP. A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography. J Thorac Oncol. 2013;8(9):1170–80.PubMedCrossRef

30.

Goksel S, Ozcelik N, Telatar G, Ardic C. The role of hematological inflammatory biomarkers in the diagnosis of lung cancer and in predicting TNM stage. Cancer Invest. 2021;39(6–7):514–20.PubMedCrossRef

31.

Xu F, Xu P, Cui W, Gong W, Wei Y, Liu B, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may aid in identifying patients with non-small cell lung cancer and predicting Tumor-Node-Metastasis stages. Oncol Lett. 2018;16(1):483–90.PubMedPubMedCentral

32.

Yip R, Li K, Liu L, Xu D, Tam K, Yankelevitz DF, et al. Controversies on lung cancers manifesting as part-solid nodules. Eur Radiol. 2018;28(2):747–59.PubMedCrossRef

33.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8(5):381–5.PubMedCrossRef

34.

Obuchowski NA, Bullen JA. Receiver operating characteristic (ROC) curves: review of methods with applications in diagnostic medicine. Phys Med Biol. 2018;63(7):07tr1.CrossRef

35.

Nattino G, Pennell ML, Lemeshow S. Assessing the goodness of fit of logistic regression models in large samples: a modification of the Hosmer-Lemeshow test. Biometrics. 2020;76(2):549–60.PubMedCrossRef

36.

Rosenfeld JP, Donchin E. Resampling (bootstrapping) the mean: a definite do. Psychophysiology. 2015;52(7):969–72.PubMedCrossRef

37.

Vickers AJ, Holland F. Decision curve analysis to evaluate the clinical benefit of prediction models. Spine J. 2021;21(10):1643–8.PubMedPubMedCentralCrossRef

38.

Huang L, Li W, Zhao L, Li B, Chai Y. Risk factors of lymph node metastasis in lung squamous cell carcinoma of 3 cm or less in diameter. Medicine (Baltimore). 2017;96(29):e7563.PubMedCrossRef

39.

Haruki T, Wakahara M, Matsuoka Y, Miwa K, Araki K, Taniguchi Y, et al. Clinicopathological characteristics of lung adenocarcinoma with unexpected lymph node metastasis. Ann Thorac Cardiovasc Surg. 2017;23(4):181–7.PubMedPubMedCentralCrossRef

40.

Xia W, Wang A, Jin M, Mao Q, Xia W, Dong G, et al. Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death. Cancer Manag Res. 2018;10:41–8.PubMedPubMedCentralCrossRef

41.

Chen B, Wang X, Yu X, Xia WJ, Zhao H, Li XF, et al. Lymph node metastasis in Chinese patients with clinical T1 non-small cell lung cancer: A multicenter real-world observational study. Thorac Cancer. 2019;10(3):533–42.PubMedPubMedCentralCrossRef

42.

Shafazand S, Gould MK. A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer. J Thorac Oncol. 2006;1(9):953–9.PubMedCrossRef

43.

Zhang Y, Sun Y, Xiang J, Zhang Y, Hu H, Chen H. A prediction model for N2 disease in T1 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;144(6):1360–4.PubMedCrossRef

44.

Zhang Y, Sun Y, Shen L, Li Y, Xiang J, Zhang Y, et al. Predictive factors of lymph node status in small peripheral non-small cell lung cancers: tumor histology is more reliable. Ann Surg Oncol. 2013;20(6):1949–54.PubMedCrossRef

45.

Li X, Zhang H, Xing L, Xu X, Xie P, Ma H, et al. Predictive value of primary fluorine-18 fluorodeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non–small-cell lung cancer. Clin Lung Cancer. 2013;14(5):568–73.PubMedCrossRef

46.

Sakao Y, Nakazono T, Sakuragi T, Natsuaki M, Itoh T. Predictive factors for survival in surgically resected clinical IA peripheral adenocarcinoma of the lung. Ann Thorac Surg. 2004;77(4):1157–61 (discussion 61-2).PubMedCrossRef

47.

Yanagitani N, Kaira K, Sunaga N, Naito Y, Koike Y, Ishihara S, et al. Serum amylase is a sensitive tumor marker for amylase-producing small cell lung cancer? Int J Clin Oncol. 2007;12(3):231–3.PubMedCrossRef

48.

Minami S, Komuta K, Asai M. A case of amylase-producing lung cancer. Nihon Kokyuki Gakkai Zasshi. 2003;41(10):717–21.PubMed

49.

Tsukawaki M, Izawa M, Yoshida M, Araki N, Hashiba Y, Nakagawa H, et al. A case of amylase-producing lung cancer. Intern Med. 1992;31(1):60–3.PubMedCrossRef

50.

Zhu J, Xu WG, Xiao H, Zhou Y. Application of a radiomics model for preding lymph node metastasis in non-small cell lung cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2019;50(3):373–8.PubMed

51.

Liang Z, Wang HF, Wu AZ, Cai JH. Clinical value of multi-tumor markers protein biochip in the diagnosis of pulmonary carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(11):2516–8.PubMed

52.

Consorti F, Lorenzotti A, Midiri G, Di Paola M. Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol. 2000;73(2):70–4.PubMedCrossRef

53.

Enciu M, Aşchie M, Deacu M, Poinăreanu I. Morphological characteristics of a mucinous adenocarcinoma of the prostate: differential diagnosis considerations. Rom J Morphol Embryol. 2013;54(1):191–4.PubMed

54.

Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Clinicopathologic characteristics and surgical outcomes of mucinous gastric carcinoma. Ann Surg Oncol. 2006;13(6):836–42.PubMedCrossRef

55.

Kawamura H, Kondo Y, Osawa S, Nisida Y, Okada K, Isizu H, et al. A clinicopathologic study of mucinous adenocarcinoma of the stomach. Gastric Cancer. 2001;4(2):83–6.PubMedCrossRef

56.

Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila). 2010;3(4):438–46.PubMedCrossRef

57.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.PubMedPubMedCentralCrossRef

58.

Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992–1001.PubMedCrossRef

59.

Cadranel J, Quoix E, Baudrin L, Mourlanette P, Moro-Sibilot D, Morere JF, et al. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol. 2009;4(9):1126–35.PubMedCrossRef

60.

Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: a clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6(9):1496–504.PubMedCrossRef

61.

Lee HY, Cha MJ, Lee KS, Lee HY, Kwon OJ, Choi JY, et al. Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas. J Thorac Oncol. 2016;11(7):1064–73.PubMedCrossRef

62.

Kadota K, Yeh YC, D’Angelo SP, Moreira AL, Kuk D, Sima CS, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol. 2014;38(8):1118–27.PubMedPubMedCentralCrossRef

63.

Kakegawa S, Shimizu K, Sugano M, Miyamae Y, Kaira K, Araki T, et al. Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer. 2011;117(18):4257–66.PubMedCrossRef

64.

Pang Z, Liu H, Chen Z, Zhu L. Establishment and validation of a novel nomogram for predicting distant metastasis in patients with invasive lung adenocarcinoma. J Coll Physicians Surg Pak. 2022;32(12):1563–9.PubMedCrossRef

65.

Tatnell PJ, Powell DJ, Hill J, Smith TS, Tew DG, Kay J. Napsins: new human aspartic proteinases. Distinction between two closely related genes. FEBS Lett. 1998;441(1):43–8.PubMedCrossRef

66.

Mori K, Kon Y, Konno A, Iwanaga T. Cellular distribution of napsin (kidney-derived aspartic protease-like protein, KAP) mRNA in the kidney, lung and lymphatic organs of adult and developing mice. Arch Histol Cytol. 2001;64(3):319–27.PubMedCrossRef

67.

Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41(1):20–5.PubMedCrossRef

68.

Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003;88(8):1229–33.PubMedPubMedCentralCrossRef

69.

Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 2010;118(6):441–9.PubMedCrossRef

70.

Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136(2):163–71.PubMedCrossRef

71.

Agackiran Y, Ozcan A, Akyurek N, Memis L, Findik G, Kaya S. Desmoglein-3 and Napsin A double stain, a useful immunohistochemical marker for differentiation of lung squamous cell carcinoma and adenocarcinoma from other subtypes. Appl Immunohistochem Mol Morphol. 2012;20(4):350–5.PubMedCrossRef

72.

Camilo R, Capelozzi VL, Siqueira SA, Del Carlo BF. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37(5):542–6.PubMedCrossRef

73.

Downey P, Cummins R, Moran M, Gulmann C. If it’s not CK5/6 positive, TTF-1 negative it’s not a squamous cell carcinoma of lung. APMIS. 2008;116(6):526–9.PubMedCrossRef

74.

Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5(4):442–7.PubMedCrossRef

Title: The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma
Authors: Mengchao Xue
Junjie Liu
Zhenyi Li
Ming Lu
Huiying Zhang
Wen Liu
Hui Tian
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Metastasis
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-11843-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Causal association of sleep traits with the risk of thyroid cancer: A mendelian randomization study

Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial

Association between psychiatric disorders and glioma risk: evidence from Mendelian randomization analysis

Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study

PErspective and current status of Radiotherapy Service in IRan (PERSIR)-1 study: assessment of current external beam radiotherapy facilities, staff and techniques compared to the international guidelines

Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer